Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Nauta IM, Balk LJ, Sonder JM, Hulst HE, Uitdehaag BM, Fasotti L, de Jong BA.

Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295. [Epub ahead of print]

PMID:
29775164
2.

Recommendations for the successful control of a large outbreak of vancomycin-resistant Enterococcus faecium in a non-endemic hospital setting.

Frakking FNJ, Bril WS, Sinnige JC, Klooster JEV, de Jong BAW, van Hannen EJ, Tersmette M.

J Hosp Infect. 2018 Feb 21. pii: S0195-6701(18)30109-9. doi: 10.1016/j.jhin.2018.02.016. [Epub ahead of print]

3.

Anxiety is more important than depression in MS - Commentary.

de Jong BA, Uitdehaag BM.

Mult Scler. 2018 Apr;24(4):444-445. doi: 10.1177/1352458518756516. Epub 2018 Jan 30. No abstract available.

4.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

5.

Why and when hierarchy impacts team effectiveness: A meta-analytic integration.

Greer LL, de Jong BA, Schouten ME, Dannals JE.

J Appl Psychol. 2018 Jun;103(6):591-613. doi: 10.1037/apl0000291. Epub 2018 Jan 25.

PMID:
29369654
6.

Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.

Bruinsma IB, van Dijk M, Bridel C, van de Lisdonk T, Haverkort SQ, Runia TF, Steinman L, Hintzen RQ, Killestein J, Verbeek MM, Teunissen CE, de Jong BA.

J Neuroinflammation. 2017 Dec 4;14(1):235. doi: 10.1186/s12974-017-1006-3.

7.

Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Nauta IM, Speckens AEM, Kessels RPC, Geurts JJG, de Groot V, Uitdehaag BMJ, Fasotti L, de Jong BA.

BMC Neurol. 2017 Nov 21;17(1):201. doi: 10.1186/s12883-017-0979-y.

8.

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

van Rooij LC, Wattjes MP, de Jong BA, van Oosten BW.

Mult Scler Relat Disord. 2017 Oct;17:54-56. doi: 10.1016/j.msard.2017.06.009. Epub 2017 Jun 29.

PMID:
29055475
9.

The Effectiveness of Mindfulness-Based Stress Reduction on Psychological Distress and Cognitive Functioning in Patients with Multiple Sclerosis: a Pilot Study.

Blankespoor RJ, Schellekens MPJ, Vos SH, Speckens AEM, de Jong BA.

Mindfulness (N Y). 2017;8(5):1251-1258. doi: 10.1007/s12671-017-0701-6. Epub 2017 Mar 28.

10.

Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.

Wagenvoort GHJ, Vlaminckx BJM, van Kessel DA, Geever RCL, de Jong BAW, Grutters JC, Bos WJW, Meek B, Rijkers GT.

Vaccine. 2017 Sep 5;35(37):4886-4895. doi: 10.1016/j.vaccine.2017.07.088. Epub 2017 Aug 9.

PMID:
28802755
11.

Trust and team performance: A meta-analysis of main effects, moderators, and covariates.

De Jong BA, Dirks KT, Gillespie N.

J Appl Psychol. 2016 Aug;101(8):1134-50. doi: 10.1037/apl0000110. Epub 2016 Apr 28.

PMID:
27123697
12.

Progressive multifocal leukoencephalopathy in an immunocompetent patient.

van der Kolk NM, Arts P, van Uden IW, Hoischen A, van de Veerdonk FL, Netea MG, de Jong BA.

Ann Clin Transl Neurol. 2016 Jan 8;3(3):226-32. doi: 10.1002/acn3.279. eCollection 2016 Mar.

13.

Reversed takotsubo cardiomyopathy in a patient with new-onset multiple sclerosis: Cause, link, or just coincidence?

Biesbroek PS, Nijveldt R, de Jong BA, van Rossum AC, van Loon RB.

Int J Cardiol. 2016 Mar 15;207:217-9. doi: 10.1016/j.ijcard.2016.01.174. Epub 2016 Jan 13. No abstract available.

PMID:
26803250
14.

Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy.

Stork AC, Cats EA, Vlam L, Heezius E, Rooijakkers S, Herpers B, de Jong BA, Rijkers G, van Strijp J, Notermans NC, van den Berg LH, van der Pol WL.

J Neuroimmunol. 2016 Jan 15;290:76-9. doi: 10.1016/j.jneuroim.2015.11.010. Epub 2015 Dec 1.

PMID:
26711574
15.

Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-specific Autoantibodies. 1998.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ.

J Immunol. 2015 Jul 1;195(1):8-16. No abstract available.

16.

Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy.

van Berge L, Hamilton EM, Linnankivi T, Uziel G, Steenweg ME, Isohanni P, Wolf NI, Krägeloh-Mann I, Brautaset NJ, Andrews PI, de Jong BA, al Ghamdi M, van Wieringen WN, Tannous BA, Hulleman E, Würdinger T, van Berkel CG, Polder E, Abbink TE, Struys EA, Scheper GC, van der Knaap MS; LBSL Research Group.

Brain. 2014 Apr;137(Pt 4):1019-29. doi: 10.1093/brain/awu026. Epub 2014 Feb 24.

PMID:
24566671
17.

Functionality of the pneumococcal antibody response in Down syndrome subjects.

Kusters MA, Manders NC, de Jong BA, van Hout RW, Rijkers GT, de Vries E.

Vaccine. 2013 Dec 16;31(52):6261-5. doi: 10.1016/j.vaccine.2013.09.070. Epub 2013 Nov 5.

PMID:
24200977
18.

Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011.

Steinman L, Axtell RC, Barbieri D, Bhat R, Brownell SE, de Jong BA, Dunn SE, Grant JL, Han MH, Ho PP, Kuipers HF, Kurnellas MP, Ousman SS, Rothbard JB.

Mult Scler. 2013 Jan;19(1):5-14. doi: 10.1177/1352458512470730.

PMID:
23303879
19.

Removal of valproic acid by plasmapheresis in a patient treated for multiple sclerosis.

Bastiaans DE, van Uden IW, Ruiterkamp RA, de Jong BA.

Ther Drug Monit. 2013 Feb;35(1):1-3. doi: 10.1097/FTD.0b013e31827b1cfa.

PMID:
23222689
20.

Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome.

Rouwette M, Somers K, Govarts C, De Deyn PP, Hupperts R, Van Wijmeersch B, De Jong BA, Verbeek MM, Van Pesch V, Sindic C, Villar LM, Álvarez-Cermeño JC, Stinissen P, Somers V.

J Neurochem. 2012 Nov;123(4):568-77. doi: 10.1111/jnc.12005. Epub 2012 Sep 28.

21.

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein.

Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, Maini A, Han MH, Killestein J, Polman C, Goodyear AL, Dunn J, Steinman L, Axtell RC.

Mult Scler. 2012 Apr;18(4):398-408. doi: 10.1177/1352458512440060. Epub 2012 Feb 16.

22.

Beyond shared perceptions of trust and monitoring in teams: implications of asymmetry and dissensus.

De Jong BA, Dirks KT.

J Appl Psychol. 2012 Mar;97(2):391-406. doi: 10.1037/a0026483. Epub 2011 Dec 19. Erratum in: J Appl Psychol. 2013 Jan;98(1):79.

PMID:
22181679
23.

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.

Lee LF, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, Shi J, de Jong BA, Killestein J, Polman CH, Steinman L, Lin JC.

Sci Transl Med. 2011 Jul 27;3(93):93ra68. doi: 10.1126/scitranslmed.3002400.

24.

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C.

Nat Med. 2010 Apr;16(4):406-12. doi: 10.1038/nm.2110. Epub 2010 Mar 28.

25.

Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes.

Herpers BL, Endeman H, de Jong BA, de Jongh BM, Grutters JC, Biesma DH, van Velzen-Blad H.

Clin Exp Immunol. 2009 Jun;156(3):488-94. doi: 10.1111/j.1365-2249.2009.03929.x.

26.

Hemolytic assay for the measurement of functional human mannose-binding lectin: a modification to avoid interference from classical pathway activation.

Herpers BL, de Jong BA, Dekker B, Aerts PC, van Dijk H, Rijkers GT, van Velzen-Blad H.

J Immunol Methods. 2009 Mar 31;343(1):61-3. doi: 10.1016/j.jim.2009.01.002. Epub 2009 Jan 24.

PMID:
19171151
27.

Deficient mannose-binding lectin-mediated complement activation despite mannose-binding lectin-sufficient genotypes in an outbreak of Legionella pneumophila pneumonia.

Herpers BL, Yzerman EP, de Jong BA, Bruin JP, Lettinga KD, Kuipers S, Den Boer JW, van Hannen EJ, Rijkers GT, van Velzen-Blad H, de Jongh BM.

Hum Immunol. 2009 Feb;70(2):125-9. doi: 10.1016/j.humimm.2008.11.002. Epub 2008 Dec 13.

PMID:
19073229
28.

Mannose-binding lectin genotypes in susceptibility to community-acquired pneumonia.

Endeman H, Herpers BL, de Jong BAW, Voorn GP, Grutters JC, van Velzen-Blad H, Biesma DH.

Chest. 2008 Dec;134(6):1135-1140. doi: 10.1378/chest.08-0642. Epub 2008 Jul 18.

PMID:
18641104
29.

Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donors.

Herpers BL, Immink MM, de Jong BA, van Velzen-Blad H, de Jongh BM, van Hannen EJ.

Mol Immunol. 2006 Mar;43(7):851-5. Epub 2005 Aug 1.

PMID:
16076493
30.

Confusing Cochrane reviews on treatment in multiple sclerosis.

de Jong BA, Engelen M, van Schaik IN, Vermeulen M.

Lancet Neurol. 2005 Jun;4(6):330-1. No abstract available.

PMID:
15907736
31.

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW.

Arthritis Rheum. 2004 Mar;50(3):709-15.

32.

Neurological recovery in obstetric brachial plexus injuries: an historical cohort study.

Hoeksma AF, ter Steeg AM, Nelissen RG, van Ouwerkerk WJ, Lankhorst GJ, de Jong BA.

Dev Med Child Neurol. 2004 Feb;46(2):76-83.

33.

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ.

Arthritis Rheum. 2003 Oct;48(10):2741-9.

34.

Quadriceps muscle strength and voluntary activation after polio.

Beelen A, Nollet F, de Visser M, de Jong BA, Lankhorst GJ, Sargeant AJ.

Muscle Nerve. 2003 Aug;28(2):218-26.

PMID:
12872327
35.

Shoulder contracture and osseous deformity in obstetrical brachial plexus injuries.

Hoeksma AF, Ter Steeg AM, Dijkstra P, Nelissen RG, Beelen A, de Jong BA.

J Bone Joint Surg Am. 2003 Feb;85-A(2):316-22.

PMID:
12571311
36.

Orthopaedic sequelae in neurologically recovered obstetrical brachial plexus injury. Case study and literature review.

ter Steeg AM, Hoeksma AF, Dijkstra PF, Nelissen RG, De Jong BA.

Disabil Rehabil. 2003 Jan 7;25(1):1-8. Review.

PMID:
12554387
37.

On autonomy and participation in rehabilitation.

Cardol M, De Jong BA, Ward CD.

Disabil Rehabil. 2002 Dec 15;24(18):970-4; discussion 975-1004. Review.

PMID:
12528676
38.

Responsiveness of the Impact on Participation and Autonomy questionnaire.

Cardol M, Beelen A, van den Bos GA, de Jong BA, de Groot IJ, de Haan RJ.

Arch Phys Med Rehabil. 2002 Nov;83(11):1524-9.

PMID:
12422319
39.

Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region.

de Jong BA, Huizinga TW, Zanelli E, Giphart MJ, Bollen EL, Uitdehaag BM, Polman CH, Westendorp RG.

Neurology. 2002 Aug 27;59(4):549-55.

PMID:
12196647
40.

Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis.

de Jong BA, Westendorp RG, Eskdale J, Uitdehaag BM, Huizinga TW.

Hum Immunol. 2002 Apr;63(4):281-5.

PMID:
12039409
41.

Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.

de Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, Remarque EJ, Burgmans AC, Kalkers NF, Polman CH, Westendorp RG.

J Neuroimmunol. 2002 May;126(1-2):172-9.

PMID:
12020968
42.

Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production.

de Jong BA, Westendorp RG, Bakker AM, Huizinga TW.

Genes Immun. 2002 Feb;3(1):25-9.

43.

Beyond disability: perceived participation in people with a chronic disabling condition.

Cardol M, de Jong BA, van den Bos GA, Beelem A, de Groot IJ, de Haan RJ.

Clin Rehabil. 2002 Feb;16(1):27-35.

PMID:
11841066
44.

Submaximal exercise capacity and maximal power output in polio subjects.

Nollet F, Beelen A, Sargeant AJ, de Visser M, Lankhorst GJ, de Jong BA.

Arch Phys Med Rehabil. 2001 Dec;82(12):1678-85.

PMID:
11733882
45.

Psychometric properties of the Impact on Participation and Autonomy Questionnaire.

Cardol M, de Haan RJ, de Jong BA, van den Bos GA, de Groot IJ.

Arch Phys Med Rehabil. 2001 Feb;82(2):210-6.

PMID:
11239312
46.

Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis.

Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, Breedveld FC, Verweij CL.

Arthritis Rheum. 2001 Jan;44(1):41-7.

47.

Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging.

Bosma GP, Rood MJ, Huizinga TW, de Jong BA, Bollen EL, van Buchem MA.

Arthritis Rheum. 2000 Nov;43(11):2428-36.

48.

Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis.

de Jong BA, Schrijver HM, Huizinga TW, Bollen EL, Polman CH, Uitdehaag BM, Kersbergen MC, Sturk A, Westendorp RG.

Ann Neurol. 2000 Oct;48(4):641-6.

PMID:
11026448
49.

The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature.

Bakker JP, de Groot IJ, Beckerman H, de Jong BA, Lankhorst GJ.

Clin Rehabil. 2000 Aug;14(4):343-59. Review.

PMID:
10945419
50.

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL.

Arthritis Rheum. 2000 Aug;43(8):1831-5.

Supplemental Content

Loading ...
Support Center